1089 related articles for article (PubMed ID: 32085836)
1. Safety and efficacy of GABA
Chabriat H; Bassetti CL; Marx U; Audoli-Inthavong ML; Sors A; Lambert E; Wattez M; Hermann DM;
Lancet Neurol; 2020 Mar; 19(3):226-233. PubMed ID: 32085836
[TBL] [Abstract][Full Text] [Related]
2. Randomized Efficacy and Safety Trial with Oral S 44819 after Recent ischemic cerebral Event (RESTORE BRAIN study): a placebo controlled phase II study.
Chabriat H; Bassetti CL; Marx U; Picarel-Blanchot F; Sors A; Gruget C; Saba B; Wattez M; Audoli ML; Hermann DM
Trials; 2020 Feb; 21(1):136. PubMed ID: 32014032
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial.
Elkins J; Veltkamp R; Montaner J; Johnston SC; Singhal AB; Becker K; Lansberg MG; Tang W; Chang I; Muralidharan K; Gheuens S; Mehta L; Elkind MSV
Lancet Neurol; 2017 Mar; 16(3):217-226. PubMed ID: 28229893
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial.
Hess DC; Wechsler LR; Clark WM; Savitz SI; Ford GA; Chiu D; Yavagal DR; Uchino K; Liebeskind DS; Auchus AP; Sen S; Sila CA; Vest JD; Mays RW
Lancet Neurol; 2017 May; 16(5):360-368. PubMed ID: 28320635
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial.
Albers GW; von Kummer R; Truelsen T; Jensen JK; Ravn GM; Grønning BA; Chabriat H; Chang KC; Davalos AE; Ford GA; Grotta J; Kaste M; Schwamm LH; Shuaib A;
Lancet Neurol; 2015 Jun; 14(6):575-84. PubMed ID: 25937443
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial.
Sharma M; Molina CA; Toyoda K; Bereczki D; Bangdiwala SI; Kasner SE; Lutsep HL; Tsivgoulis G; Ntaios G; Czlonkowska A; Shuaib A; Amarenco P; Endres M; Yoon BW; Tanne D; Toni D; Yperzeele L; von Weitzel-Mudersbach P; Sampaio Silva G; Avezum A; Dawson J; Strbian D; Tatlisumak T; Eckstein J; Ameriso SF; Weber JR; Sandset EC; Goar Pogosova N; Lavados PM; Arauz A; Gailani D; Diener HC; Bernstein RA; Cordonnier C; Kahl A; Abelian G; Donovan M; Pachai C; Li D; Hankey GJ
Lancet Neurol; 2024 Jan; 23(1):46-59. PubMed ID: 38101902
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial.
François B; Jafri HS; Chastre J; Sánchez-García M; Eggimann P; Dequin PF; Huberlant V; Viña Soria L; Boulain T; Bretonnière C; Pugin J; Trenado J; Hernandez Padilla AC; Ali O; Shoemaker K; Ren P; Coenjaerts FE; Ruzin A; Barraud O; Timbermont L; Lammens C; Pierre V; Wu Y; Vignaud J; Colbert S; Bellamy T; Esser MT; Dubovsky F; Bonten MJ; Goossens H; Laterre PF;
Lancet Infect Dis; 2021 Sep; 21(9):1313-1323. PubMed ID: 33894131
[TBL] [Abstract][Full Text] [Related]
8. Effects of the Selective α5-GABAAR Antagonist S44819 on Excitability in the Human Brain: A TMS-EMG and TMS-EEG Phase I Study.
Darmani G; Zipser CM; Böhmer GM; Deschet K; Müller-Dahlhaus F; Belardinelli P; Schwab M; Ziemann U
J Neurosci; 2016 Dec; 36(49):12312-12320. PubMed ID: 27927951
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial.
Hill MD; Goyal M; Menon BK; Nogueira RG; McTaggart RA; Demchuk AM; Poppe AY; Buck BH; Field TS; Dowlatshahi D; van Adel BA; Swartz RH; Shah RA; Sauvageau E; Zerna C; Ospel JM; Joshi M; Almekhlafi MA; Ryckborst KJ; Lowerison MW; Heard K; Garman D; Haussen D; Cutting SM; Coutts SB; Roy D; Rempel JL; Rohr AC; Iancu D; Sahlas DJ; Yu AYX; Devlin TG; Hanel RA; Puetz V; Silver FL; Campbell BCV; Chapot R; Teitelbaum J; Mandzia JL; Kleinig TJ; Turkel-Parrella D; Heck D; Kelly ME; Bharatha A; Bang OY; Jadhav A; Gupta R; Frei DF; Tarpley JW; McDougall CG; Holmin S; Rha JH; Puri AS; Camden MC; Thomalla G; Choe H; Phillips SJ; Schindler JL; Thornton J; Nagel S; Heo JH; Sohn SI; Psychogios MN; Budzik RF; Starkman S; Martin CO; Burns PA; Murphy S; Lopez GA; English J; Tymianski M;
Lancet; 2020 Mar; 395(10227):878-887. PubMed ID: 32087818
[TBL] [Abstract][Full Text] [Related]
10. Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial.
Gusev EI; Martynov MY; Nikonov AA; Shamalov NA; Semenov MP; Gerasimets EA; Yarovaya EB; Semenov AM; Archakov AI; Markin SS;
Lancet Neurol; 2021 Sep; 20(9):721-728. PubMed ID: 34418399
[TBL] [Abstract][Full Text] [Related]
11. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial.
Logallo N; Novotny V; Assmus J; Kvistad CE; Alteheld L; Rønning OM; Thommessen B; Amthor KF; Ihle-Hansen H; Kurz M; Tobro H; Kaur K; Stankiewicz M; Carlsson M; Morsund Å; Idicula T; Aamodt AH; Lund C; Næss H; Waje-Andreassen U; Thomassen L
Lancet Neurol; 2017 Oct; 16(10):781-788. PubMed ID: 28780236
[TBL] [Abstract][Full Text] [Related]
12. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial.
Bluhmki E; Chamorro A; Dávalos A; Machnig T; Sauce C; Wahlgren N; Wardlaw J; Hacke W
Lancet Neurol; 2009 Dec; 8(12):1095-102. PubMed ID: 19850525
[TBL] [Abstract][Full Text] [Related]
13. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial.
Anderson CS; Huang Y; Lindley RI; Chen X; Arima H; Chen G; Li Q; Billot L; Delcourt C; Bath PM; Broderick JP; Demchuk AM; Donnan GA; Durham AC; Lavados PM; Lee TH; Levi C; Martins SO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Silva F; Song L; Thang NH; Wardlaw JM; Wang JG; Wang X; Woodward M; Chalmers J; Robinson TG;
Lancet; 2019 Mar; 393(10174):877-888. PubMed ID: 30739745
[TBL] [Abstract][Full Text] [Related]
14. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
[TBL] [Abstract][Full Text] [Related]
15. An injectable implant to stimulate the sphenopalatine ganglion for treatment of acute ischaemic stroke up to 24 h from onset (ImpACT-24B): an international, randomised, double-blind, sham-controlled, pivotal trial.
Bornstein NM; Saver JL; Diener HC; Gorelick PB; Shuaib A; Solberg Y; Thackeray L; Savic M; Janelidze T; Zarqua N; Yarnitsky D; Molina CA;
Lancet; 2019 Jul; 394(10194):219-229. PubMed ID: 31133406
[TBL] [Abstract][Full Text] [Related]
16. Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial.
Pan Y; Meng X; Yuan B; Johnston SC; Li H; Bath PM; Dong Q; Xu A; Jing J; Lin J; Jiang Y; Xie X; Jin A; Suo Y; Yang H; Feng Y; Zhou Y; Liu Q; Li X; Liu B; Zhu H; Zhao J; Huang X; Li H; Xiong Y; Li Z; Wang Y; Zhao X; Liu L; Wang Y;
Lancet Neurol; 2023 Jun; 22(6):485-493. PubMed ID: 37121237
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of intra-arterial bone marrow mononuclear cell transplantation in patients with acute ischaemic stroke in Spain (IBIS trial): a phase 2, randomised, open-label, standard-of-care controlled, multicentre trial.
Moniche F; Cabezas-Rodriguez JA; Valverde R; Escudero-Martinez I; Lebrato-Hernandez L; Pardo-Galiana B; Ainz L; Medina-Rodriguez M; de la Torre J; Escamilla-Gomez V; Ortega-Quintanilla J; Zapata-Arriaza E; de Albóniga-Chindurza A; Mancha F; Gamero MA; Perez S; Espinosa-Rosso R; Forero-Diaz L; Moya M; Piñero P; Calderón-Cabrera C; Nogueras S; Jimenez R; Martin V; Delgado F; Ochoa-Sepúlveda JJ; Quijano B; Mata R; Santos-González M; Carmona-Sanchez G; Herrera C; Gonzalez A; Montaner J
Lancet Neurol; 2023 Feb; 22(2):137-146. PubMed ID: 36681446
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
[TBL] [Abstract][Full Text] [Related]
19. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial.
Shoamanesh A; Mundl H; Smith EE; Masjuan J; Milanov I; Hirano T; Agafina A; Campbell B; Caso V; Mas JL; Dong Q; Turcani P; Christensen H; Ferro JM; Veltkamp R; Mikulik R; De Marchis GM; Robinson T; Lemmens R; Stepien A; Greisenegger S; Roine R; Csiba L; Khatri P; Coutinho J; Lindgren AG; Demchuk AM; Colorado P; Kirsch B; Neumann C; Heenan L; Xu L; Connolly SJ; Hart RG;
Lancet; 2022 Sep; 400(10357):997-1007. PubMed ID: 36063821
[TBL] [Abstract][Full Text] [Related]
20. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
